In this podcast, Lorenza Rimassa and Alejandro Forner summarize four abstracts orally presented during the ESMO annual congress held in Paris in September 2022.
Three abstracts report the results of first-line phase 3 trials of immunotherapy for unresectable hepatocellular carcinoma, and one trial reports the results of a phase 1/2 trial of a new FGFR inhibitor for cholangiocarcinoma.
HCC
LEAP-002 trial tested the combination of pembrolizumab and lenvatinib versus lenvatinib single agent and did not meet its primary endpoints. A second combination trial evaluated the combination of camrelizumab and rivoceranib versus sorafenib in a mostly Asian population showing the superiority of the combination compared to sorafenib, with a higher rate of adverse events. RATIONALE-301 assessed single-agent tislelizumab versus sorafenib demonstrating the non-inferiority of tislelizumab compared to sorafenib with a good safety profile.
CCA
The ReFocus study evaluated a new highly selective FGFR2 inhibitor in patients with cholangiocarcinoma with FGFR2 fusions previously treated with chemotherapy, showing impressive efficacy results and a good safety profile.
Incyte has co-funded this podcast and all content has been developed independently by ILCA.
